BioStamp nPoint is a wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings during research studies. These physiological data include heart rate variability, respiration rate, activity (including step count and activity classification), and posture (body position relative to gravity). The system is also intended for measurement of surface electromyography, and to monitor limb or body living and sleep. Data are transmitted wirelessly from the Sensors for storage and analysis.

The device is intended for use on general care patients who are 18 years of age or older as a general patient monitor, to provide physiological information. The BioStamp nPoint system are only intended for use by researchers and healthcare professionals for research applications, including at the discretion of a qualified healthcare professional as an aid to diagnosis and treatment in the context of clinical research and product development. The device is not intended for use on critical care patients, and is not a real time or remote diagnostic device.

Device Description

The BioStamp nPoint system is a wireless remote monitoring platform intended for use by healthcare professionals and researchers for the continuous collection of physiological data in home and healthcare settings. The system is designed only for data collection during research studies.

The BioStamp nPoint system centers on body-worn Wearable Sensor Patches (WSPs) and can be used in both clinic and home settings for up to 24 hours. Study facilitators (either researchers or physicians) set up data collection studies using a web-based study configuration tool, called the Investigator Portal. For supervised uses, the BioStamp nPoint system includes a Tablet with Investigator Application that study facilitators use to connect to and configure WSPs. When used at home, study subjects interact with the system through the Mobile Phone Link Application. The Link Hub is used to charge and synchronize data from the Wearable Sensor Patches. The BioStamp nPoint system includes an algorithm package that delivers processed metrics on general activity classification, heart rate, heart rate variability, posture, sleep, and respiration during sleep. The BioStamp nPoint system is intended for use on general care patients who are 18 years of age or older and is not intended for use on critical care patients.

AI/ML Overview

The BioStamp nPoint device is a wireless remote monitoring system. The provided text offers details about its performance validation, but it does not include a specific table of acceptance criteria with reported device performance metrics, nor does it describe an AI-specific study.

However, based on the information provided, we can infer and construct some aspects of the performance study and how it relates to general acceptance criteria for medical devices of this type.

Here's an attempt to answer your request, gleaning information from the provided text and making reasonable inferences where specific details are missing:

The BioStamp nPoint system is a wireless remote monitoring platform. While the document does not explicitly state acceptance criteria in a table format with corresponding performance results, it indicates that "V&V testing was performed to establish the safety and effectiveness of BioStamp nPoint." The device's performance was evaluated against its intended use for measuring physiological data.

1. Acceptance Criteria and Reported Device Performance

Given the nature of the device, the implicit acceptance criteria would revolve around the accuracy, reliability, and safety of its physiological data collection.

Inferred Acceptance Criteria Table and General Performance Statement:

Physiological Data Metric	Acceptance Criteria (Inferred)	Reported Device Performance
Heart Rate	Accurate and reliable measurement within clinically acceptable limits compared to a reference standard.	"The results of the clinical investigation demonstrate an effectiveness profile that is similar to the predicate devices." (Exact accuracy metrics are not provided in this summary.)
Heart Rate Variability	Accurate and reliable measurement within clinically acceptable limits compared to a reference standard.	"The results of the clinical investigation demonstrate an effectiveness profile that is similar to the predicate devices." (Exact accuracy metrics are not provided in this summary.)
Respiration Rate	Accurate and reliable measurement within clinically acceptable limits compared to a reference standard.	"The results of the clinical investigation demonstrate an effectiveness profile that is similar to the predicate devices." (Exact accuracy metrics are not provided in this summary.)
Activity/Step Count	Accurate and reliable measurement compared to a reference standard, demonstrating appropriate classification of general activity and step count.	"The results of the clinical investigation demonstrate an effectiveness profile that is similar to the predicate devices." (Exact accuracy metrics are not provided in this summary.)
Posture	Accurate and reliable classification/measurement of body position relative to gravity.	"The results of the clinical investigation demonstrate an effectiveness profile that is similar to the predicate devices." (Exact accuracy metrics are not provided in this summary.)
Surface Electromyography (EMG)	Accurate and reliable measurement of surface electromyography.	The document states comparison to the CMAP Pro (K113074) predicate device found equivalence in technological characteristics related to EMG data gathering, implying acceptable performance. (Specific performance metrics are not given.)
Limb/Body Movements (Sleep/Daily Living)	Accurate and reliable monitoring and analysis of physiological motion during daily living and sleep.	The document states comparison to the MotionWatch and PRO-Diary (K132764) predicate device found equivalence in technological characteristics related to measuring and analyzing physiological motion, implying acceptable performance. (Specific performance metrics are not given.)
Safety	Compliance with relevant electrical safety and EMC standards.	"Safety testing demonstrated the device complies with IEC 60601-1 Edition 3.1, IEC 60601-1-11:2015, IEC 60601-1-6, IEC 62366:2015, IEC 60601-2-40:2016." and "EMC testing was conducted and demonstrated the device complies with IEC 60601-1-2 Edition 4. and FCC CFR 47 Part 15 Subpart C for wireless communication."
Biocompatibility	No adverse biological reactions when in contact with the body.	"Biocompatibility testing included cytotoxicity, irritation, and sensitization according to the recommendations of ISO 10993-1, Biological evaluation of medical devices – Part 1: Evaluation and testing." (Implies compliance was achieved).
Software Functionality	Software operates as intended without critical errors impacting safety or effectiveness.	"Software V&V testing was performed... and demonstrated safety and effectiveness of the device." (Software was determined to be a "moderate level of concern").

2. Sample Size and Data Provenance for the Test Set:

Sample Size for Test Set: 30 healthy volunteers were used for the human clinical investigation.
Data Provenance: The document states "A human clinical investigation was performed on 30 healthy volunteers." It does not specify the country of origin, but given the FDA submission, it's likely the study was conducted in the US or in a manner compliant with US regulations. The study was a prospective clinical investigation.

3. Number of Experts and Qualifications for Ground Truth:

The document does not specify the number or qualifications of experts used to establish ground truth for the physiological measurements. It only mentions that the study evaluated the device's performance at measuring various physiological parameters. For physiological measurements, ground truth is typically established by comparative methods using validated reference instruments.

4. Adjudication Method for the Test Set:

The document does not mention any adjudication method for the test set, as this typically applies to subjective interpretations (e.g., image reading) rather than direct physiological measurements validated against a reference.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

No, a MRMC comparative effectiveness study was not done. This type of study is more common for diagnostic imaging AI systems where human readers interpret images with or without AI assistance.
The BioStamp nPoint is a physiological data collection device, not an AI-assisted diagnostic tool for human interpretation. Therefore, a MRMC study is not applicable in this context.

6. Standalone (Algorithm Only) Performance:

The document describes the device as a "wireless remote monitoring system" with an "algorithm package that delivers processed metrics." The clinical investigation on 30 healthy volunteers evaluated the "performance of the device at measuring heart rate, heart rate variability, respiratory rate, activity (including step count and activity classification), and posture (body position relative to gravity)." This implies that the standalone performance of the device's algorithms in processing the raw sensor data into these metrics was assessed. The results were compared to predicate devices, suggesting the performance was deemed acceptable.

7. Type of Ground Truth Used:

The ground truth for the human clinical investigation would have been established by comparison to established, accurate, and preferably gold-standard reference methods or devices for measuring each physiological parameter (e.g., a reference ECG for heart rate, a capnograph or spirometer for respiration rate, or direct observation/other validated accelerometry for activity/step count). The document does not explicitly state the specific ground truth methods but refers to "effectiveness profile that is similar to the predicate devices," implying a comparison to known, validated physiological measurements.

8. Sample Size for the Training Set:

The document does not provide information regarding the sample size for a training set. This is not unexpected, as the device is for physiological data collection, and while it uses "algorithms," the context doesn't indicate a machine learning model that would require a large, independently defined "training set" in the sense of a dataset used to train a deep learning algorithm. If the algorithms are signal processing or rule-based, a separate "training set" may not exist in the same way.

9. How Ground Truth for Training Set was Established:

As no training set is described, this information is not applicable/provided.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

May 8, 2018

MC10 Inc. % Jonathan Kahan Partner Hogan Lovells 555 13th St. NW Washington, District of Columbia 20004

Re: K173510

Trade/Device Name: BioStamp nPoint Regulation Number: 21 CFR 870.2910 Regulation Name: Radiofrequency Physiological Signal Transmitter And Receiver Regulatory Class: Class II Product Code: DRG, IKN, LEL, MWI Dated: April 6, 2018 Received: April 6, 2018

Dear Jonathan Kahan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);

{1}------------------------------------------------

Page 2 - Jonathan Kahan

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

M.A. Wilhelm

for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

510(k) Number (if known)

K173510

Device Name

BioStamp nPoint

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
Residential Use (With DEP-issued Septage Disposal Permit)	One-Time Application (With DEP-issued Septage Disposal Permit)

|X Prescription Use (Part 21 CFR 801 Subpart D)

[ ] Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

K173510

510(k) SUMMARY

MC10 Inc.'s BioStamp nPoint

Submitter

MC10 Inc.,

10 Maguire Road, Bldg 3, First Floor Lexington, MA 02421

Phone: 857-214-5600 Facsimile: 781-538-6641

Contact Person: Rakesh Lal, Director of Quality and Requlatory

Strategy Date Prepared: May 4, 2018

Name of Device: BioStamp nPoint

Common or Usual Name: Wireless Remote Monitoring System

Classification Name: Transmitters and Receivers, Physiological Signal, Radiofrequency

Regulation: 21 CFR 870.2910;

Requlatory Class: Class II

Product Code: DRG Other: IKN. LEL. MWI

Predicate Devices

Primary predicate: Vital Connect Platform, Healthpatch MD, VitalPatch (K152139)

Subsequent predicate: MotionWatch and PRO-Diary (K132764)

Subsequent predicate: Comprehensive Muscular Activity Profiler Pro (CMAP Pro) (K113074)

Device Description

{4}------------------------------------------------

system includes a Tablet with Investigator Application that study facilitators use to connect to and configure WSPs. When used at home, study subjects interact with the system through the Mobile Phone Link Application. The Link Hub is used to charge and synchronize data from the Wearable Sensor Patches. The BioStamp nPoint system includes an algorithm package that delivers processed metrics on general activity classification, heart rate, heart rate variability, posture, sleep, and respiration during sleep. The BioStamp nPoint system is intended for use on general care patients who are 18 years of age or older and is not intended for use on critical care patients.

System Component	Description
Investigator Portal	Website for study facilitators to design supervised andremote studies, enroll subjects, and visualize studydata
Investigator Portal(Algorithm Package)	Cloud-based algorithm package to process raw WSPdata into algorithm outputs
Wearable Sensor Patches(WSPs)	Wearable Sensor Patches that can be configured to avariety of sensing modalities and worn in variouslocations on the body
Adhesives	Single-use adhesive stickers for placing WSPs onto thebody
Tablet and Investigator App	Tablet based app for study facilitators to initiate datacollection. The tablet and app are provided by MC10and shipped with the system.
Mobile Phone and SyncApplication	Smartphone based app for facilitators to upload WSPdata in the lab
Mobile Phone and LinkApplication	Smartphone based app for subjects to receive studyinstructions, tag activities, input survey entries andcontrol the Wearable Sensor Patches. The phone andapp are provided by MC10 and shipped with thesystem.
Link Hub	Station for charging and transferring data from theWSPs and Mobile Phone Apps

The BioStamp nPoint system is comprised of the following components:

Intended Use / Indications for Use

BioStamp nPoint is a wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and

{5}------------------------------------------------

professional healthcare settings during research studies. These physiological data include heart rate, heart rate variability, respiration rate, activity (including step count and activity classification), and posture (body position relative to gravity). The system is also intended for measurement of surface electromyography, and to monitor limb or body movements during daily living and sleep. Data are transmitted wirelessly from the Sensors for storage and analysis.

The device is intended for use on general care patients who are 18 years of age or older as a general patient monitor, to provide physiological information. The data from the BioStamp nPoint system are only intended for use by researchers and healthcare professionals for research applications, including at the discretion of a qualified healthcare professional as an aid to diagnosis and treatment in the context of clinical research and product development. The device is not intended for use on critical care patients, and is not a real time or remote diagnostic device.

Summary of Technological Characteristics

A comparison of the technological characteristics of the subject device to the primary predicate, the Vital Connect Platform (K152139), was performed, and it was determined that both devices were largely equivalent to each other in terms of their technological characteristics and methods of operations, and any difference did not raise different questions of safety and effectiveness.

The technological characteristics of the subject device were also compared to the CMAP Pro (K113074) predicate device, and it was determined that both devices were largely equivalent to each other in terms of their technological characteristics related to EMG data gathering, and any difference did not raise different questions of safety and effectiveness.

The technological characteristics of the subject device were also compared to the MotionWatch and PRO-Diary (K132764) predicate device, and it was determined that both devices were largely equivalent to each other in terms of their technological characteristics related to measuring and analyzing physiological motion of the body during daily living and sleep, and any difference did not raise different questions of safety and effectiveness.

Note: The BioStamp nPoint system is not intended to be used for the display of an ECG waveform. The BioStamp nPoint system not intended to be used to detect heart rate in patients with arrhythmia, or ventricular ectopic beats. The respiratory rate function is not intended to provide information to diagnose or treat disease. The respiratory rate function is not for measuring of irregular breathing rhythms.

Performance Data

V&V testing was performed to establish the safety and effectiveness of BioStamp nPoint, and the following performance data has been provided to support the substantial equivalence determination.

Biocompatibility testing included cytotoxicity, irritation, and sensitization according to the recommendations of ISO 10993-1, Biological evaluation of medical devices – Part 1: Evaluation and testing.

{6}------------------------------------------------

Safety testing demonstrated the device complies with IEC 60601-1 Edition 3.1, IEC 60601-1-11:2015, IEC 60601-1-6, IEC 62366:2015, IEC 60601-2-40:2016. EMC testing was conducted and demonstrated the device complies with IEC 60601-1-2 Edition 4. and FCC CFR 47 Part 15 Subpart C for wireless communication.

Software V&V testing was performed in accordance with FDA's Guidance for Industry and FDA Staff, Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices. The software contained in the device is determined to be a moderate level of concern, and software V&V testing demonstrated safety and effectiveness of the device.

A human clinical investigation was performed on 30 healthy volunteers to evaluate the performance of the device at measuring heart rate, heart rate variability, respiratory rate, activity (including step count and activity classification), and posture (body position relative to gravity). No adverse events related to the device were encountered, and the results of the clinical investigation demonstrate an effectiveness profile that is similar to the predicate devices.

Conclusions

The BioStamp nPoint has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate devices. The minor differences in indications do not alter the intended diagnostic use of the device and do not affect its safety and effectiveness when used as labeled. In addition, the minor technological differences between the BioStamp nPoint and its predicate devices raise no new issues of safety or effectiveness. Performance data demonstrate that the BioStamp nPoint is substantially equivalent to the predicate devices.

Regulation Number and Section

§ 870.2910 Radiofrequency physiological signal transmitter and receiver.

(a)
Identification. A radiofrequency physiological signal transmitter and receiver is a device used to condition a physiological signal so that it can be transmitted via radiofrequency from one location to another, e.g., a central monitoring station. The received signal is reconditioned by the device into its original format so that it can be displayed.(b)
Classification. Class II (performance standards).